Vaccinating High-Risk Children with the Intranasal Live-Attenuated Influenza Vaccine: The Quebec Experience

Paediatric Respiratory Reviews

Volumn 15, Issue 4, 2014, Pages 340-347

  Quach, Caroline ^a,b  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

Author keywords

Asthma; Children; Cystic fibrosis; Live attenuated influenza vaccine

Indexed keywords

INFLUENZA VACCINE; PLACEBO; LIVE VACCINE;

CANADA; CHILD; CYSTIC FIBROSIS; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HIGH RISK PATIENT; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; INFLUENZA VIRUS A; LUNG DISEASE; MUCOSAL IMMUNITY; NOSE MUCOSA; NOSE OBSTRUCTION; RESPIRATORY VIRUS; REVIEW; RHINORRHEA; TERTIARY HEALTH CARE; VACCINATION; VIROLOGY; CHRONIC DISEASE; INFLUENZA, HUMAN; INTRANASAL DRUG ADMINISTRATION; RISK FACTOR;

ADMINISTRATION, INTRANASAL; CHILD; CHRONIC DISEASE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; RISK FACTORS; VACCINES, ATTENUATED;

EID: 84918571254     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2014.06.002     Document Type: Review

References (47)

1. Public Health Agency of Canada (PHAC). Canadian immunization guide - active vaccines - influenza. 2012; Available at Accessed 2014-06-07. http://www.phac-aspc.gc.ca/publicat/cig-gci/p04-influenza-eng.php.
2. Public Health Agency of Canada (PHAC). Reported influenza hospitalizations and deaths in canada: 2009-10 to 2013-14 (data to may 31, 2014). 2014; Available at Accessed 2014-06-07. http://www.phac-aspc.gc.ca/influenza/flu-stat-eng.php.
3. Centers for Disease Control and Prevention (CDC). Fluview: A weekly influenza surveillance report prepared by the influenza division; 2013-2014 influenza season week 22 ending may 31, 2014. 2014; Available at Accessed 2014-06-07. http://www.cdc.gov/flu/weekly/index.htm.
4. World Health Organization (WHO). Influenza. 2008; Available at Accessed 2014-06-07. http://www.who.int/immunization/topics/influenza/en/.
5. World Health Organization (WHO). Influenza at the human-animal interface (hai). 2014; Available at Accessed 2014-06-07. http://www.who.int/influenza/human_animal_interface/en/.
6. Ferson M.J., Morton J.R., Robertson P.W. Impact of influenza on morbidity in children with cystic fibrosis. Journal of paediatrics and child health 1991, 27:308-311.
7. Wat D., Gelder C., Hibbitts S., Cafferty F., Bowler I., Pierrepoint M., et al. The role of respiratory viruses in cystic fibrosis. Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society 2008, 7:320-328.
8. Viviani L., Assael B.M., Kerem E. Impact of the a (h1n1) pandemic influenza (season 2009-2010) on patients with cystic fibrosis. Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society 2011, 10:370-376.
9. Kwon J.M., Shim J.W., Kim D.S., Jung H.L., Park M.S., Shim J.Y. Prevalence of respiratory viral infection in children hospitalized for acute lower respiratory tract diseases, and association of rhinovirus and influenza virus with asthma exacerbations. Korean J Pediatr 2014, 57:29-34.
10. Dawood F.S., Kamimoto L., D'Mello T.A., Reingold A., Gershman K., Meek J., et al. Children with asthma hospitalized with seasonal or pandemic influenza, 2003-2009. Pediatrics 2011, 128:e27-e32.
11. National Advisory Committee on Immunization (NACI). Recommendations on the use of live, attenuated influenza vaccine (flumist) - supplemental statement on seasonal influenza vaccine for 2011-2012 Canada Communicable Disease Report 2011;37:1-77.
12. Petukhova G., Korenkov D., Chirkova T., Donina S., Rudenko L., Naykhin A. B- and t-cell memory elicited by a seasonal live attenuated reassortant influenza vaccine: Assessment of local antibody avidity and virus-specific memory t-cells using trogocytosis-based method. Influenza and other respiratory viruses 2012, 6:119-126.
13. Fischer Ii W.A., Chason K.D., Brighton M., Jaspers I. Live attenuated influenza vaccine strains elicit a greater innate immune response than antigenically-matched seasonal influenza viruses during infection of human nasal epithelial cell cultures. Vaccine 2014, 32:1761-1767.
14. Block S.L., Yogev R., Hayden F.G., Ambrose C.S., Zeng W., Walker R.E. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine 2008, 26:4940-4946.
15. Ambrose C.S., Wu X., Knuf M., Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: A meta-analysis of 8 randomized controlled studies. Vaccine 2012, 30:886-892.
16. Ashkenazi S., Vertruyen A., Aristegui J., Esposito S., McKeith D.D., Klemola T., et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006, 25:870-879.
17. Fleming D.M., Crovari P., Wahn U., Klemola T., Schlesinger Y., Langussis A., et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006, 25:860-869.
18. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. The New England journal of medicine 2007, 356:685-696.
19. Ohmit S.E., Victor J.C., Rotthoff J.R., Teich E.R., Truscon R.K., Baum L.L., et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006, 355:2513-2522.
20. Ohmit S.E., Victor J.C., Teich E.R., Truscon R.K., Rotthoff J.R., Newton D.W., et al. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis 2008, 198:312-317.
21. Monto A.S., Ohmit S.E., Petrie J.G., Johnson E., Truscon R., Teich E., et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009, 361:1260-1267.
22. Forrest B.D., Steele A.D., Hiemstra L., Rappaport R., Ambrose C.S., Gruber W.C. A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older. Vaccine 2011, 29:3633-3639.
23. Belshe R.B., Toback S.L., Yi T., Ambrose C.S. Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. Influenza Other Respir Viruses 2010, 4:141-145.
24. Haber P, Arana J, Walton K. Safety of live attenuated influenza vaccine in children aged 24-59 months, vaccine adverse event reporting system (vaers), 2007-2009. 49th ICAAC, San Francisco 2009.
25. Ambrose C.S., Dubovsky F., Yi T., Belshe R.B., Ashkenazi S. The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology 2012, 31:2549-2557.
26. Cates C.J., Rowe B.H. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev 2013, 2:CD000364.
27. Redding G., Walker R.E., Hessel C., Virant F.S., Ayars G.H., Bensch G., et al. Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2002, 21:44-48.
28. Atmar R.L., Bloom K., Keitel W., Couch R.B., Greenberg S.B. Effect of live attenuated, cold recombinant (cr) influenza virus vaccines on pulmonary function in healthy and asthmatic adults. Vaccine 1990, 8:217-224.
29. Gaglani M.J., Piedra P.A., Riggs M., Herschler G., Fewlass C., Glezen W.P. Safety of the intranasal, trivalent, live attenuated influenza vaccine (laiv) in children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J 2008, 27:444-452.
30. Dharmaraj P., Smyth R.L. Vaccines for preventing influenza in people with cystic fibrosis. Cochrane Database Syst Rev 2014, 3:CD001753.
31. King J.C., Gross P.A., Denning C.R., Gaerlan P.F., Wright P.F., Quinnan G.V. Comparison of live and inactivated influenza vaccine in high risk children. Vaccine 1987, 5:234-238.
32. Gruber W.C., Campbell P.W., Thompson J.M., Reed G.W., Roberts B., Wright P.F. Comparison of live attenuated and inactivated influenza vaccines in cystic fibrosis patients and their families: Results of a 3-year study. The Journal of infectious diseases 1994, 169:241-247.
33. Conese M. Cystic fibrosis and the innate immune system: Therapeutic implications. Endocrine, metabolic & immune disorders drug targets 2011, 11:8-22.
34. Bonfield T.L., Panuska J.R., Konstan M.W., Hilliard K.A., Hilliard J.B., Ghnaim H., et al. Inflammatory cytokines in cystic fibrosis lungs. American journal of respiratory and critical care medicine 1995, 152:2111-2118.
35. Muhlebach M.S., Stewart P.W., Leigh M.W., Noah T.L. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. American journal of respiratory and critical care medicine 1999, 160:186-191.
36. Muhlebach M.S., Reed W., Noah T.L. Quantitative cytokine gene expression in cf airway. Pediatric pulmonology 2004, 37:393-399.
37. Kube D., Sontich U., Fletcher D., Davis P.B. Proinflammatory cytokine responses to p. Aeruginosa infection in human airway epithelial cell lines. Am J Physiol Lung Cell Mol Physiol 2001, 280:L493-L502.
38. McKeon D.J., Condliffe A.M., Cowburn A.S., Cadwallader K.C., Farahi N., Bilton D., et al. Prolonged survival of neutrophils from patients with delta f508 cftr mutations. Thorax 2008, 63:660-661.
39. Boikos C., DeSerres G., Lands L.C., Boucher F.D., Tapiero B., Daigneault P., et al. Safety of live-attenuated influenza vaccination in cystic fibrosis. Pediatrics 2014, 134. In Press.
40. Protocole d'immunisation du québec. 2013; Available at Accessed 2014-06-07. http://publications.msss.gouv.qc.ca/acrobat/f/documentation/piq/piq_complet.pdf.
41. Schaad U.B., Buhlmann U., Burger R., Ruedeberg A., Wilder-Smith A., Rutishauser M., et al. Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis. Antimicrob Agents Chemother 2000, 44:1163-1167.
42. National Advisory Committee on Immunization (NACI). Recommendations on the use of live, attenuated influenza vaccine (flumist): Supplemental statement on seasonal influenza vaccine 2011-2012. Canada Communicable Disease Report 2011;37:37.
43. National Advisory Committee on Immunization (NACI). Statement on seasonal influenza vaccine for 2013-2014. Canada Communicable Disease Report 2013;39:37.
44. Quach C, Boulianne N, Comité sur l'immunisation du Québec (CIQ). Use of live-attenuated influenza virus vaccine (laiv), flumist in children and adolescents aged 2-17 years of age with chronic conditions Quebec: Institut national de santé publique du Québec (INSPQ); 2012,10. http://www.inspq.qc.ca/pdf/publications/1454_UtilisVVAIEnfantAdo2-17MalChron_VA.pdf.
45. Dube E, Gagnon D, Huot C, Pare R, Jacques S, Kossowski A, et al. Influenza immunization of chronically ill children in paediatric tertiary care hospitals. Human Vaccines & Immunotherapeutics 2014;In Press.
46. Merckx J, Dube E, Boulianne N, Landry M, Valiquette L, McCormack D, et al. Influenza vaccination in chronically ill children: A strategy to imrpove vaccination coverage. In: ID Week 2013. San Francisco, CA, USA; 2013, abstract.
47. Merckx J, Landry M, Valiquette L, McCormack D, Quach C. Influenza vaccination in chronically ill children: Taking a closer look at laiv. In: ID Week 2014. Philadelphia, PA, USA; 2014, abstract.